The startup develops ultra-wide imaging technology that enhances image resolution for skin cancer diagnosis and surgical guidance. Its handheld 3D imaging device visualizes the shape and profile of suspicious tissue, allowing dermatologists to accurately assess margins before biopsy and improve excision precision.
Funding
$260K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for skin cancer diagnosis often rely on visual inspection and biopsies, which can be subjective, time-consuming, and invasive. Accurately assessing the margins of suspicious tissue before excision is challenging, potentially leading to incomplete removal or excessive tissue removal.
Solution
The startup provides an ultra-wide imaging technology designed to improve skin cancer diagnosis and surgical precision. Their handheld 3D imaging device captures detailed shape and profile data of suspicious tissue, enabling dermatologists to visualize subsurface structures and assess lesion margins more accurately. This enhanced visualization facilitates better pre-biopsy assessment and more precise surgical excisions, potentially reducing the need for repeat procedures and improving patient outcomes. The technology aims to provide a non-invasive, objective method for evaluating skin lesions.
Target Audience
The primary users are dermatologists and surgeons who require improved visualization and assessment tools for skin cancer diagnosis and surgical planning.
Features
- Handheld 3D imaging device for visualizing skin lesions
- Ultra-wide imaging technology to enhance image resolution
- Detailed shape and profile mapping of suspicious tissue
- Subsurface visualization capabilities